HOG
26
-4
EW
36
-8
EMR
54
-3
KLAC
58
-3
MNST
45
-4
GM
44
-3
AMZN
53
-2
IPG
35
-4
TXN
33
-5
FTI
66
-8
MLM
29
-3
BF.B
25
-4
PWR
57
3
ORLY
41
-3
WDC
40
-2
BDX
63
-2
MSI
43
-4
ACN
50
-6
DFS
60
-8
USB
50
-3
HOG
26
-4
EW
36
-8
EMR
54
-3
KLAC
58
-3
MNST
45
-4
GM
44
-3
AMZN
53
-2
IPG
35
-4
TXN
33
-5
FTI
66
-8
MLM
29
-3
BF.B
25
-4
PWR
57
3
ORLY
41
-3
WDC
40
-2
BDX
63
-2
MSI
43
-4
ACN
50
-6
DFS
60
-8
USB
50
-3
Financhill
Back

Beam Therapeutics 10K Form

Sell
47

BEAM
Beam Therapeutics

Last Price:
$26.38
Seasonality Move:
-20.08%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-08 10Q BEAM/Beam Therapeutics Quarterly
2023-08-08 10Q BEAM/Beam Therapeutics Quarterly
2023-05-10 10Q BEAM/Beam Therapeutics Quarterly
2022-11-07 10Q BEAM/Beam Therapeutics Quarterly
2022-08-09 10Q BEAM/Beam Therapeutics Quarterly
2022-05-09 10Q BEAM/Beam Therapeutics Quarterly

Receive BEAM News And Ratings

See the #1 stock for the next 7 days that we like better than BEAM

BEAM Financial Statistics

Sales & Book Value

Annual Sales: $377.7M
Cash Flow: $-89.7M
Price / Cash Flow: 0
Annual Sales: $9.58
Price / Book: 2.76

Profitability

EPS (TTM): -1.76000
Net Income (TTM): $-143.6M
Gross Margin: $1.5B
Return on Equity: -16.62%
Return on Assets: -10.97%

Beam Therapeutics Earnings Forecast

Key Beam Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for BEAM is 58.08%.
  • The Selling, General & Administrative Expenses for BEAM have been equal to 30.93% of Gross Profit Margin.
  • The Research & Development expenses have been 115.80% of Revenue.
  • The Net Earning history of BEAM is -35.09% of Total Revenues.
  • Per Share Earnings over the last 16 years have been positive in 6 years.

Beam Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BEAM
CUSIP: 07373V
Website: beamtx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.69
Quick Ratio: 5.57

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BEAM Technical Analysis vs Fundamental Analysis

Sell
47
Beam Therapeutics (BEAM) is a Sell

Is Beam Therapeutics a Buy or a Sell?

  • Beam Therapeutics stock is rated a Sell
    The current Beam Therapeutics [BEAM] share price is $26.39. The Score for BEAM is 47, which is 6% below its historic median score of 50, and infers higher risk than normal.